A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Psoriasis Treated With Ustekinumab and Other Types of Biological and Systemic Non-biological Treatments.

Trial Profile

A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Psoriasis Treated With Ustekinumab and Other Types of Biological and Systemic Non-biological Treatments.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Antipsoriatics; Tumour necrosis factor inhibitors
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 10 Feb 2017 Planned number of patients changed from 1000 to 2000.
    • 23 Apr 2012 Actual initiation date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Planned number of patients 1000 added as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top